AU
BMRN icon

AlphaGrep UK’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaGrep UK’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Buy
5,851
+1,145
+24% +$62.7K 0.1% 409
2026
Q1 		$266K Buy
+4,706
New +$274K 0.08% 568

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AlphaGrep UK's BMRN Position: Q2 2026 in Review

AlphaGrep UK increased its BioMarin Pharmaceuticals (BMRN) stake by 24% in Q2 2026, buying an estimated $62.7K and bringing the position to 5,851 shares worth $335K. The position accounts for 0.1% of the portfolio, ranked #409.

AlphaGrep UK first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • AlphaGrep UK held 5,851 shares of BioMarin Pharmaceuticals worth $335K as of Q2 2026.
  • AlphaGrep UK bought 1,145 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $62.7K.
  • BioMarin Pharmaceuticals made up 0.1% of AlphaGrep UK's portfolio in Q2 2026, its #409 holding.
  • AlphaGrep UK first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.